IP Library Granted Patent US 7,432,355
Granted Patent B2
US 7,432,355 · App. 10/626,415 · Granted Oct 7, 2008

Apolipoprotein E stable folding intermediate and methods of use thereof

Assignee: The J. David Gladstone Institutes
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,432,355
App. No.
10/626,415
Granted
Oct 7, 2008
Kind
B2
Abstract

The present invention provides isolated apolipoprotein E (apoE) stable folding intermediates. The invention further provides methods for identifying compounds that alter the structure or level or activity of an apoE stable folding intermediate, as well as methods of inhibiting the formation or activity of stable folding intermediates of apoE. The invention further provides methods for reducing the level and/or activity of an apoE stable folding intermediate, and methods for treating disorders relating to apoE4 in a subject.

Claims (10)

1. A composition comprising an isolated apolipoprotein E (i.e., apoE) stable folding intermediate, wherein the apoE stable folding intermediate is at least about 80% pure, wherein the apoE is apoE3 or apoE4, and wherein the stable folding intermediate is formed at a pH of from about 1.0 to about 5.0.

2. The composition of claim 1 , wherein the apoE stable folding intermediate comprises an N-terminal fragment of apoE4.

3. The composition of claim 1 , wherein the apoE stable folding intermediate is at least about 90% pure.

4. The composition of claim 1 , wherein the apoE stable folding intermediate comprises an N-terminal fragment of apoE3.

5. The composition of claim 1 , wherein the apoE stable folding intermediate is formed at a pH of from about 2.0 to about 4.0.

6. The composition of claim 1 , wherein the apoE stable folding intermediate is formed at a urea concentration of from about 2 M to about 7 M.

7. The composition of claim 1 , wherein the apoE is apoE4, and wherein the apoE stable folding intermediate is formed at a urea concentration of from about 3.5 M to about 4.5 M.

8. The composition of claim 1 , wherein the apoE is apoE3, and wherein the apoE stable folding intermediate is formed at a urea concentration of from about 4.5 M to about 5 M.

9. The composition of claim 2 , wherein the N-terminal fragment of apoE4 is about 22 kDa in size.

10. The composition of claim 4 , wherein the N-terminal fragment of apoE3 is about 22 kDa in size.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jul 16, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024699/0532 →
CONFIRMATORY LICENSE Recorded Oct 27, 2008
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021743/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2006
From: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
To: J. DAVID GLADSTONE INSTITUTES, THE
Reel/Frame 017595/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2004
From: WEISGRABER, KARL H.; MORROW, JULIE A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 015537/0727 →
Continuity (2)
Provisional Application 6040247000 · Aug 9, 2002
Related Publication 20040228851A1 · Nov 18, 2004